SemiVoice

seekingalpha

01/06/2025, 05:13 AM UTC

Aquestive Therapeutics：2025年的五大重点Aquestive Therapeutics: Five Foci For 2025

1、Aquestive Therapeutics的Anaphylm接近FDA批准，可能颠覆美国过敏性休克的药物市场；2、AQST-108，一种用于斑秃的局部肾上腺素凝胶，显示出希望；3、Libervant，一种用于簇状发作的苯二氮卓类药物颊膜，获得了孤儿药独家权。

1. Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market; 2. AQST-108, a topical epinephrine gel for alopecia areata, shows promise; 3. Libervant, a diazepam buccal film for cluster seizures, has gained orphan drug exclusivity.

---

本文由大语言模型（LLM）生成，旨在为读者提供半导体新闻内容的知识扩展（Beta）。